Skip to main content

Table 4 Adverse event profiling of amikacin inhalation (n = 26)

From: The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases

Adverse event

Number (%)

Auditory toxicity

1 (3.8)

Renal toxicity

0 (0.0)

Uncomfortable feeling in the oral cavity

12 (46.2)

Oral candidiasis

1 (3.8)

Hoarseness

5 (19.2)

Dysphonia

1 (3.8)

Pneumothorax

1 (3.8)

Hemoptysis

1 (3.8)

Digestive symptom

1 (3.8)

Vertigo

1 (3.8)

Epistaxis

1 (3.8)